| Literature DB >> 29124061 |
Krzysztof Kaliszewski1, Dorota Diakowska2, Marta Strutyńska-Karpińska3, Beata Wojtczak1, Michał Aporowicz1, Zdzisław Forkasiewicz1, Waldemar Balcerzak1, Tadeusz Łukieńczuk1, Paweł Domosławski1.
Abstract
BACKGROUND: It seems valuable for clinicians to know if diagnostics of thyroid malignancy (TM) and indications for surgery in the elderly patients differ from these in younger counterparts.Entities:
Mesh:
Year: 2017 PMID: 29124061 PMCID: PMC5662825 DOI: 10.1155/2017/1012451
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Baseline characteristics of 3,749 patients with thyroid nodules.
| Parameters | Mean ± SD or |
|---|---|
| Age (years) | 51.4 ± 14.4 |
|
| |
| Female | 3,148 (84.0) |
| Male | 601 (16.0) |
|
| |
| Stage II (normotype thyrocytes, lymphocytes, thyroiditis suspicion) | 3,206 (85.5) |
| Stage III (AUS/FLUS) | 84 (2.2) |
| Stage IV (follicular neoplasm) | 225 (6.0) |
| Stage V (malignancy suspicion) | 48 (1.3) |
| Stage V (malignancy/lymphoma suspicion) | 2 (0.1) |
| Stage VI (papillary carcinoma) | 178 (4.7) |
| Stage VI (medullary carcinoma) | 6 (0.2) |
|
| |
| No | 3,290 (87.8) |
| Yes | 459 (12.2) |
|
| |
| Benign multinodular goiter | 2,946 (78.6) |
| Thyroiditis | 118 (3.1) |
| Follicular carcinoma | 25 (0.7) |
| Papillary carcinoma | 247 (6.6) |
| Medullary carcinoma | 10 (0.3) |
| Undifferentiated thyroid carcinoma | 9 (0.3) |
| Secondary malignant tumor | 4 (0.1) |
| Lymphoma | 9 (0.2) |
| Follicular adenoma | 375 (10.0) |
| Squamous cell carcinoma | 1 (0.03) |
| Abscess | 1 (0.03) |
|
| |
| Benign | 3,440 (91.8) |
| Malignant | 309 (8.2) |
TBSRTC: The Bethesda System for Reporting Thyroid Cytology, Second Edition 2010 Bethesda, Maryland; AUS: atypia of undetermined significance; FLUS: follicular lesion of undetermined significance.
Distribution of cases according to gender and age parameters. Data were presented as number (percent).
| Female | Male | |||||||
|---|---|---|---|---|---|---|---|---|
| <45 years ( | ≥45–<65 years ( | ≥65 years ( |
| <45 years ( | ≥45–<65 years ( | ≥65 years ( |
| |
|
| ||||||||
| Stage II (normotype thyrocytes, lymphocytes, thyroiditis suspicion) | 841 (84.5) | 1,382 (87.3) | 448 (78.7) | <0.0001 | 151 (84.8) | 261 (91.6) | 123 (89.1) | 0.254 |
| Stage III (AUS/FLUS) | 26 (2.6) | 34 (2.2) | 13 (2.3) | 5 (2.8) | 4 (1.4) | 2 (1.5) | ||
| Stage IV (follicular neoplasm) | 65 (6.5) | 87 (5.5) | 50 (8.8) | 12 (6.7) | 8 (2.8) | 3 (2.2) | ||
| Stage V (malignancy suspicion) | 3 (0.3) | 15 (1.0) | 21 (3.7) | 3 (1.7) | 2 (0.7) | 4 (2.9) | ||
| Stage V (malignancy/lymphoma suspicion) | 0 (0.0) | 0 (0.0) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Stage VI (papillary carcinoma) | 59 (5.9) | 62 (3.9) | 34 (6.0) | 7 (3.9) | 10 (3.5) | 6 (4.4) | ||
| Stage VI (medullary carcinoma) | 1 (0.1) | 4 (0.3) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
|
| ||||||||
|
| ||||||||
| No | 867 (87.1) | 1,416 (89.4) | 461 (81.0) | <0.0001 | 156 (87.6) | 265 (93.0) | 125 (90.6) | 0.157 |
| Yes | 128 (12.9) | 168 (10.6) | 108 (19.0) | 22 (12.4) | 20 (7.0) | 13 (9.4) | ||
|
| ||||||||
|
| ||||||||
| Trachea compression | 278 (32.1) | 720 (50.9) | 444 (96.3) | <0.0001 | 46 (30.0) | 117 (43.8) | 112 (89.6) | <0.0001 |
| Recent tumor/goiter enlargement | 205 (23.6) | 284 (20) | 8 (1.7) | 79 (50.0) | 49 (18.8) | 7 (5.6) | ||
| Urgent indication (acute respiratory failure/retrosternal goiter) | 0 (0.0) | 0 (0.0) | 7 (1.5) | 0 (0.0) | 0 (0.0) | 4 (3.2) | ||
| Cosmetic indication | 384 (44.3) | 412 (29.1) | 2 (0.4) | 31 (20.0) | 99 (37.5) | 2 (1.6) | ||
|
| ||||||||
|
| ||||||||
| Benign multinodular goiter | 759 (76.3) | 1,281 (81.0) | 433 (76.1) | <0.0001 | 131 (73.6) | 236 (82.8) | 105 (76.1) | 0.001 |
| Thyroiditis | 36 (3.6) | 50 (3.2) | 20 (3.5) | 7 (3.9) | 3 (1.1) | 2 (1.5) | ||
| Follicular carcinoma | 7 (0.7) | 5 (0.3) | 5 (0.9) | 0 (0.0) | 1 (0.4) | 7 (5.1) | ||
| Papillary carcinoma | 76 (7.6) | 96 (6.1) | 44 (7.7) | 9 (5.1) | 18 (6.3) | 4 (2.9) | ||
| Medullary carcinoma | 2 (0.2) | 2 (0.1) | 3 (0.5) | 2 (1.1) | 1 (0.4) | 0 (0.0) | ||
| Undifferentiated thyroid cancer | 0 (0.0) | 1 (0.1) | 6 (1.1) | 0 (0.0) | 1 (0.4) | 1 (0.7) | ||
| Secondary malignant tumor | 0 (0.0) | 1 (0.1) | 2 (0.4) | 0 (0.0) | 0 (0.0) | 1 (0.7) | ||
| Lymphoma | 0 (0.0) | 2 (0.1) | 6 (1.1) | 0 (0.0) | 1 (0.4) | 0 (0.0) | ||
| Squamous cell carcinoma | 0 (0.0) | 0 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Adenoma | 115 (11.6) | 142 (9.0) | 47 (8.3) | 29 (16.3) | 24 (8.4) | 18 (13.0) | ||
| Abscess | 0 (0.0) | 1 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
|
| ||||||||
|
| ||||||||
| Benign | 910 (91.5) | 1,474 (93.1) | 501 (88.1) | 0.002 | 167 (93.8) | 263 (92.3) | 125 (90.6) | 0.561 |
| Malignant | 85 (8.5) | 110 (6.9) | 68 (11.9) | 11 (6.2) | 22 (7.7) | 13 (9.4) | ||
|
| ||||||||
|
| ||||||||
| No | 995 (100.0) | 1,572 (99.2) | 472 (83.0) | <0.0001 | 178 (100.0) | 285 (100.0) | 130 (94.2) | <0.0001 |
| Yes | 0 (0.0) | 12 (0.8) | 97 (17.0) | 0 (0.0) | 0 (0.0) | 8 (5.8) | ||
TBSRTC: The Bethesda System for Reporting Thyroid Cytology, Second Edition 2010 Bethesda, Maryland; AUS: atypia of undetermined significance; FLUS: follicular lesion of undetermined significance; statistically significant.
Analyses of correlation between clinical suspicion of malignancy and final diagnosis of thyroid malignancy presence.
| Total ( | <45 years ( | ≥45–<65 years ( | ≥65 years ( | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| Female | ||||||||
| Clinical suspicion of malignancy & final diagnosis | 0.543 | <0.0001 | 0.581 | <0.0001 | 0.503 | <0.0001 | 0.554 | <0.0001 |
|
| ||||||||
| Male | ||||||||
| Clinical suspicion of malignancy & final diagnosis | 0.560 | <0.0001 | 0.542 | <0.0001 | 0.590 | <0.0001 | 0.575 | <0.0001 |
Statistically significant.
Diagnostic potential of clinical suspicion of malignancy parameter in prediction of thyroid malignant tumor presence in total study group and age subgroups of patients with thyroid nodules (ROC analysis).
| Total study group ( | <45 years ( | ≥45–<65 years ( | ≥65 years ( | |
|---|---|---|---|---|
| AUC | 0.825 | 0.850 | 0.800 | 0.829 |
| 95% CI | 0.790–0.855 | 0.800–0.900 | 0.751–0.850 | 0.772–0.885 |
|
| <0.0001 | <0.0001 | <0.0001 | <0.0001 |
| SE | 0.015 | 0.026 | 0.025 | 0.029 |
| Sensitivity | 0.72 | 0.77 | 0.66 | 0.75 |
| Specificity | 0.93 | 0.93 | 0.94 | 0.90 |
| Accuracy | 0.91 | 0.92 | 0.92 | 0.89 |
| LR(+) | 10.43 | 10.92 | 11.33 | 7.86 |
| LR(−) | 0.30 | 0.25 | 0.36 | 0.27 |
| PPV | 0.48 | 0.49 | 0.46 | 0.50 |
| NPV | 0.97 | 0.98 | 0.97 | 0.97 |
| Youden's index | 0.65 | 0.70 | 0.60 | 0.66 |
AUC: area under ROC curve; 95% CI: confidence interval; SE: standard error; LR(+): likelihood ratio of positive results; LR(−): likelihood ratio of negative results; PPV: positive predictive value; NPV: negative predictive value; statistically significant.
Clinical and pathological characteristics of thyroid malignancy (TM) patients (n = 309) divided into three subgroups according to age parameter. Data were presented as n (%).
|
| <45 years ( | ≥45–<65 years ( | ≥65 years ( |
| |
|---|---|---|---|---|---|
| Gender | |||||
| Female | 263 | 85 (88,5) | 110 (83.3) | 68 (84.0) | 0.520 |
| Male | 46 | 11 (11.5) | 22 (16.7) | 13 (16.0) | |
|
| |||||
| Type of surgery | |||||
| Radical | 202 | 65 (67.7) | 82 (66.7) | 46 (63,0) | 0.803 |
| Nonradical | 107 | 31 (32.3) | 41 (33.3) | 27 (37.0) | |
|
| |||||
| Reoperation | |||||
| No | 217 | 70 (72.9) | 87 (70.7) | 50 (70.4) | 0.919 |
| Yes | 92 | 26 (27.1) | 36 (29.3) | 21 (29.6) | |
|
| |||||
| pTNM | |||||
| I | 199 | 88 (91.7) | 84 (67.2) | 23 (31.9) | <0.0001 |
| II | 48 | 5 (5.2) | 21 (16.8) | 18 (25.0) | |
| III | 31 | 1 (1.0) | 11 (8.8) | 15 (20.8) | |
| IV | 31 | 2 (2.1) | 9 (7.2) | 16 (22.2) | |
|
| |||||
| pT | |||||
| T1a | 125 | 45 (47.9) | 62 (49.2) | 16 (22.2) | <0.0001 |
| T1b | 68 | 31 (32.9) | 26 (20.6) | 8 (11.1) | |
| T2 | 56 | 15 (15.9) | 19 (15.1) | 19 (26.3) | |
| T3 | 25 | 1 (1.0) | 8 (6.4) | 13 (18.1) | |
| T4a | 17 | 2 (2.1) | 8 (6.4) | 4 (5.6) | |
| T4b | 18 | 0 (0.0) | 3 (2.3) | 12 (16.7) | |
|
| |||||
| pN | |||||
| N0 | 148 | 49 (51.0) | 60 (47.6) | 35 (48.6) | 0.071 |
| N1a | 42 | 12 (12.5) | 12 (9.5) | 14 (19.4) | |
| N1b | 20 | 5 (5.2) | 4 (3.2) | 7 (9.7) | |
| Nx | 99 | 30 (31.3) | 50 (39.7) | 16 (22.2) | |
|
| |||||
| pM | |||||
| M0 | 218 | 77 (80.2) | 87 (69.1) | 54 (75.0) | 0.032 |
| M1 | 6 | 0 (0.0) | 2 (1.6) | 4 (5.6) | |
| Mx | 85 | 19 (19.8) | 37 (29.3) | 14 (19.4) | |
|
| |||||
| Type of nodule | |||||
| Solitary | 223 | 71 (73.9) | 88 (69.8) | 56 (77.8) | 0.468 |
| Multiple | 86 | 25 (26.1) | 38 (30.2) | 16 (22.2) | |
Statistically significant.